Atorvastatin treatment attenuates renal injury in an experimental model of ischemia-reperfusion in rats

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Wu, Kefei ^a   Lei, Wenjing ^a   Tian, Jianwei ^a   Li, Hongyan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ATORVASTATIN; CREATININE; DRUG VEHICLE; INTERCELLULAR ADHESION MOLECULE 1; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MECHANISM; EXPERIMENTAL MODEL; INFLAMMATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY NECROSIS; KIDNEY TUBULE CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; UPREGULATION;

ACUTE KIDNEY INJURY; ANIMALS; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; MALE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; TREATMENT OUTCOME;

EID: 84892737690     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-14     Document Type: Article

References (28)

1. Acute renal failure in critically ill patients: a multinational, multicenter study. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, JAMA 2005 294 813 818 10.1001/jama.294.7.813 16106006
2. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. Schrier RW, Wang W, Poole B, Mitra A, J Clin Invest 2004 114 5 14 15232604
3. Use of dopamine in acute renal failure: a meta-analysis. Kellum JA, Decker JM, Crit Care Med 2001 29 1526 1531 10.1097/00003246-200108000-00005 11505120
4. Anaritide in acute tubular necrosis: auriculin anaritide acute renal failure study group. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, Sayegh MH, N Engl J Med 1997 336 828 834 10.1056/NEJM199703203361203 9062091
5. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J, McKeown W, O'shea M, Baughman R, Wood K, Haupt M, Kaiser R, Simms H, Warnock D, Summer W, Hintz R, Myers B, Haenftling K, Capra W, et al. Kidney Int 1999 55 2423 2432 10.1046/j.1523-1755.1999.00463.x 10354291
6. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR, J Biol Chem 2002 277 21453 21457 10.1074/jbc.C200176200 11967257
7. Inflammatory cells in ischemic acute renal failure. Friedewald JJ, Rabb H, Kidney Int 2004 66 486 491 10.1111/j.1523-1755.2004.761-3.x 15253694
8. CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in proximal tubule cells. Li H, Nord EP, Am J Physiol Renal Physiol 2002 282 1020 F1033 11997318
9. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H, J Am Soc Nephrol 2002 13 2288 2298 10.1097/01.ASN.0000026609.45827.3D 12191973
10. Atorvastatin improves the course of ischemic acute renal failure in aging rats. Sabbatini M, Pisani A, Uccello F, Serio V, Serù R, Paternò R, Cianciaruso B, Fuiano G, Andreucci M, J Am Soc Nephrol 2004 15 901 909 10.1097/01.ASN.0000119573.01290.AE 15034092
11. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H, Am J Nephrol 2003 23 13 17 10.1159/000066301 12373076
12. Effects of statins on renal function after aortic cross clamping during major vascular surgery. Schouten O, Kok NF, Boersma E, Bax JJ, Feringa HH, Vidakovic R, van Eps RG S, van Sambeek MR, Poldermans D, Am J Cardiol 2006 97 1383 1385 10.1016/j.amjcard.2005.11.063 16635616
13. Statins and renal diseases: from primary prevention to renal replacement therapy. D'Amico G, J Am Soc Nephrol 2006 17 148 S152 10.1681/ASN.2005121341 16565241
14. Acute protective effects of simvastatin in the rat model of renal ischemia-reperfusion injury: it is never too late for the pretreatment? Todorovic Z, Nesic Z, Stojanović R, Basta-Jovanović G, Radojevic-Skodrić S, Velicković R, Chatterjee PK, Thiemermann C, Prostran M, J Pharmacol Sci 2008 107 465 470 10.1254/jphs.SC0070374 18719319
15. Oxygen free radicals in ischemic acute renal failure in the rat. Paller MS, Hoidal JR, Ferris TF, J Clin Invest 1984 74 1156 1164 10.1172/JCI111524 6434591
16. Trigonella foenum graecum seed extract protects kidney function and morphology in diabetic rats via its antioxidant activity. Xue W, Lei J, Li X, Zhang R, Nutr Res 2011 31 555 562 10.1016/j.nutres.2011.05.010 21840472
17. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B, Kidney Int 1996 49 1304 1313 10.1038/ki.1996.186 8731095
18. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Satoh K, Clin Chim Acta 1978 90 37 43 10.1016/0009-8981(78) 90081-5 719890
19. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM, Mackenzie HS, Am J Physiol Renal Physiol 2001 280 343 F355 11208610
20. The role of advanced oxidation protein products in intensive care unit patients with acute kidney injury. Lentini P, de Cal M, Cruz D, Chronopoulos A, Soni S, Nalesso F, Zanella M, Garzotto F, Brendolan A, Piccinni P, Ronco C, J Crit Care 2010 25 605 609 10.1016/j.jcrc.2010.04.006 20537505
21. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Piwowar A, Pol Merkur Lekarski 2010 28 166 169 20369749
22. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. Li HY, Hou FF, Zhang X, Chen PY, Liu SX, Feng JX, Liu ZQ, Shan YX, Wang GB, Zhou ZM, Tian JW, Xie D, J Am Soc Nephrol 2007 18 528 538 10.1681/ASN.2006070781 17202414
23. Advanced oxidation protein products as prognostic biomarkers for recovery from acute kidney injury after coronary artery bypass grafting. Liang X, Chen Y, Zhuang J, Zhang M, Xiong W, Guo H, Jiang F, Hu P, Guo D, Shi W, Biomarkers 2012 17 507 512 10.3109/1354750X.2012.690103 22616978
24. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Janero DR, Free Radic Biol Med 1990 9 515 540 10.1016/0891-5849(90)90131-2 2079232
25. Rapid, sensitive, and specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food, and feedstuff samples. Botsoglou NA, Fletouris DJ, Papageorgiou GE, Florou-Paner P, Mantis AJ, J Agric Food Chem 1994 42 1931 1937 10.1021/jf00045a019
26. Lovastatin protects mithochondrial and renal function in kidney ischemia-reperfusion in rats. Tucci Junior S, Molina CA, Cassini MF, Leal DM, Schineider CA, Martins AC, Acta Cir Bras 2012 27 477 481 10.1590/S0102- 86502012000700008 22760833
27. Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: possible role for aldose-reductase inhibition. Gottmann U, Brinkkoetter PT, Hoeger S, Gutermann K, Coutinho ZM, Ruf T, Hui S, Liu Z, Schnuelle P, van der Woude FJ, Braun C, Yard BA, Transplantation 2007 84 755 762 10.1097/01.tp.0000281410.85659.48 17893609
28. Atorvastatin improving renal ischemia reperfusion injury via direct inhibition of active caspase-3 in rats. Haylor JL, Harris KP, Nicholson ML, Waller HL, Huang Q, Yang B, Exp Biol Med (Maywood) 2011 236 755 763 10.1258/ebm.2011.010350 21558089